Workshop will be held at the North American Adoptive T Cell Therapy Congress in Boston on June 28, 2016, from 9am to 12pm
Valbonne, France, June 14, 2016 – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, today announces that Arnaud Foussat, Chief Scientific Officer of TxCell, will chair the world’s first workshop dedicated to adoptive T cell therapy with Tregs for treating autoimmunity, inflammation and transplantation.
The panel of speakers at the workshop includes world-leading authors on the pioneering field of Tregs and CAR-Tregs. This includes Zelig Eshhar, the inventor of the CAR concept, Kate MacDonald, who recently published a unique preclinical proof-of-concept with human CAR-Treg cells, James Riley, co-founder of Tmunity, Qizhi Tang, a pioneer in the translation of Treg cell-based research to the clinic, and Ignacio Anegon, an expert in immuno-regulation.
The workshop will be held at the North American Adoptive T Cell Therapy Congress in Boston on June 28, 2016, from 9am to 12pm.
The panel will discuss the progress and challenges of clinical development of Treg cell-based therapy as well as new evidence for Treg cell therapeutic efficacy in preclinical settings. Topics will include manufacturing of Treg cell-based products, clinical trials with Tregs in autoimmunity and transplantation, generation and therapeutic efficacy of CAR-Treg cells, and new Treg subtypes showing therapeutic benefit in transplantation. The panel will also be answering questions from delegates.
The full summary is available at http://tcellcongressusa.com/workshop-day.
About TxCell – www.txcell.com
TxCell is a publicly listed biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need. TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated. Ovasave(R), TxCell’s lead drug candidate, is currently in a Phase IIb clinical trial in refractory Crohn’s disease patients. Col-Treg, its second drug candidate, is in preclinical development for the treatment of autoimmune uveitis. Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 50 employees.
